FDA approves Combigan

November 26, 2007

The FDA has approved Allergan's Combigan for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

The FDA has approved Allergan's Combigan for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.

Combigan (brimonidine tartrate/timolol maleate) ophthalmic solution is an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor. In pivotal 12-month trials, the drug significantly reduced mean IOP by up to 7.6 mmHg from baseline and was found to be well tolerated.